Pro-Inflammatory Cytokines in Patients With Chronic Phase-Chronic Myeloid Leukaemia Treated With Imatinib: Any Role in the Monitoring of Treatment Response?
Background: Cancers cause changes in the levels of inflammatory cytokines by inhibiting or promoting their production thus affecting the immune system. The measurement of serum levels of cytokines may be useful in assessing these immunological changes and invariably assessing cancer status. Objectiv...
Saved in:
| Main Authors: | Kehinde A. Taiwo, Ibrahim O. Ahmed, Muritala A. Asafa, Olusola J. Olarewaju, Oludolapo A. Omoyiola, Olatokunbo O. Oguns, Temilola O. Owojuyigbe, Rahman A. Bolarinwa |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-06-01
|
| Series: | Biomarker Insights |
| Online Access: | https://doi.org/10.1177/11772719251351687 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Intravitreal Bevacizumab and Triamcinolone for Treatment of Cystoid Macular Oedema Associated with Chronic Myeloid Leukaemia and Imatinib Therapy
by: Eric K. Newcott, et al.
Published: (2015-01-01) -
Treatment efficacy of chronic myeloid leukemia with imatinib in clinical practice
by: A. K. Golenkov, et al.
Published: (2014-07-01) -
Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01) -
Chronic myeloid leukemia — before and after imatinib (First part)
by: E. G. Lomaia, et al.
Published: (2022-11-01) -
Chronic myeloid leukemia — before and after imatinib (Third part)
by: E. G. Lomaia, et al.
Published: (2022-11-01)